Endogenex taps former Medtronic executive as CEO

Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO.

Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its novel ReCET procedure. ReCET a novel, endoscopic, outpatient procedure, targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute to the development and progression of type 2 diabetes.

Read the full story at Drug Delivery Business News »

Scroll to Top